Supernus Pharmaceuticals (SUPN) EBIT Growth (5y) (2016 - 2026)
Supernus Pharmaceuticals (SUPN) EBIT Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.90% |
| Dec 31, 2025 | -15.90% |
| Sep 30, 2025 | -25.17% |
| Mar 31, 2025 | -18.67% |
| Dec 31, 2024 | -12.11% |
| Sep 30, 2024 | 0.56% |
| Jun 30, 2024 | -11.93% |
| Mar 31, 2024 | -16.26% |
| Dec 31, 2023 | -15.16% |
| Sep 30, 2023 | -26.32% |
| Jun 30, 2023 | -20.04% |
| Mar 31, 2023 | -30.27% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | -15.64% |
| Jun 30, 2022 | -15.33% |
| Mar 31, 2022 | -34.87% |
| Dec 31, 2021 | -17.85% |
| Sep 30, 2021 | 10.45% |
| Jun 30, 2021 | 23.98% |
| Mar 31, 2021 | 15.47% |